Research Progress of Esomeprazole and its Potential Risk for Administration

• 作者: Fotian Xie Yi Lv
• 来源期刊: 中国生物医学工程学报（英文版）
• 年，卷（期）: 2020,（2）
• 所属期刊栏目: Review
• 页码范围: 37-45
• 页数: 9页
• 语种: 英文

摘要

Esomeprazole, one of the proton pump inhibitors (PPIs), has been widely used in acid-related diseases, such as gastro-esophageal reflux disease and Helicobacter pylori infection. Compared with other PPIs, esomeprazole has higher acid control efficiency, bioavailability, stability, and less interindividual variation depending on its pharmacokinetic properties. Esomeprazole was considered safe for long-term administration. However, several recent studies have contradicted its abso-lute safety, and some detrimental cases have been reported in some special groups, such as pregnant women and patients with liver cirrhosis. Because acid-related diseases usually require long-term therapy and esomeprazole inhibits CYP2C19 enzyme that increases the probability of drug-drug interaction, these risks have become a concern. Recent studies have shown that esomeprazole not only inhibits acid secretion, but also exhibits acid-independent effects in inflammatory condi-tions. Esomeprazole can modulate NF-κb activation to resist tissue oxidation and apoptosis in gastric ulcer. In CCL4-in-duced liver fibrosis, esomeprazole improves oxidative stress, fibrogenesis, and apoptosis, but the mechanism still remains unclear. This review summarized the property of esomeprazole and its potential risk for administration, and its latest re-search progress, which may facilitate clinicians to better use and avoid the potential risks.